Request Free Sample ×
Inhaled Nitric Oxide No Delivery System Market Research Report — Global Forecast till 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Inhaled Nitric Oxide No Delivery System Market

ID: MRFR/CnM/23355-HCR
111 Pages
Chitranshi Jaiswal
Last Updated: April 23, 2026

Inhaled Nitric Oxide No Delivery System Market Research Report: By Inhaled Nitric Oxide Concentration (100 ppm, 200 ppm, 300 ppm, 400 ppm, 500 ppm), By Delivery System (Nasal Cannula, Tracheal Tube, Ventilator, Face Mask), By Patient Population (Newborns, Children, Adults, Older Adults), By Indication (Pulmonary Hypertension, Respiratory Distress Syndrome, Asthma, Chronic Obstructive Pulmonary Disease), By End User (Hospitals, Clinics, Ambulatory Surgery Centers) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Inhaled Nitric Oxide No Delivery System Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
⚠ CRITICAL SUPPLY CHAIN & PRICE VOLATILITY ALERT
Middle East Conflict Disrupts Chemical Feedstock Flows & Triggers Price Volatility Across Naphtha, LPG, Natural Gas Derivatives, Steel Feedstocks & Fertilizers — 20% of Global LNG Exports at Risk, Supply Chains Rerouting | Get Real-Time Impact Analysis, Pricing Scenarios & Alternative Sourcing Strategies

Inhaled Nitric Oxide No Delivery System Market Summary

As per Market Research Future analysis, the Inhaled Nitric Oxide No Delivery System Market. Size was estimated at 1.268 USD Billion in 2024. The Inhaled Nitric Oxide No Delivery System industry is projected to grow from 1.354 USD Billion in 2025 to 2.619 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 6.82% during the forecast period 2025 - 2035
 
Key Market Facts 2025-2035  

Metric 2025 Value 2035 Projection CAGR
Global Market Size USD 1.354B USD 2.619B 6.82%
North America USD 542M (40%) USD 1.048B 6.8% ← DOMINANT
Asia Pacific USD 406M (30%) USD 786M 6.9% ← FASTEST
Europe USD 271M (20%) USD 524M 6.7%
Fastest Growing Concentrations  
Concentration 2025 Share CAGR Key Application
300 ppm 42.1% 7.4% DOMINANT - Adult PH/ARDS rescue
200 ppm 28.6% 7.8% FASTEST - Neonatal transition
100 ppm 18.4% 6.5% PPHN standard
By Delivery System  
Delivery System 2025 Share FiO₂ Range Patient Group
Ventilator 68.4% 21-100% NICU/ICU (±0.1ppm precision)
Nasal Cannula 19.2% 24-44% Non-invasive neonates
Face Mask 7.5% 35-60% Pediatrics
Tracheal Tube 4.9% 100% Surgical
By Patient Population  
Population 2025 Share Incidence
Newborns 62.3% 1:1,000 births (PPHN)
Adults 22.1% PH/ARDS
Children 10.6% Ped ARDS
Older Adults 5.0% COPD/PH
By Indication  
Indication 2025 Share Evidence Level
Pulmonary Hypertension 48.7% FDA/EMA approved
Respiratory Distress Syndrome 28.4% Neonatal standard
COPD/Asthma 22.9% Emerging
By End User  
End User 2025 Share Capacity
Hospitals 82.6% NICU/ICU dominance
Clinics/ASC 17.4% Outpatient PH
Regional Leadership
North America (40%): Largest market, advanced NICUs, INOmax® leadership
Asia Pacific (30%): Fastest growing, preterm birth surge (15M/year), urbanization
Europe (20%): EMA guidelines, national health systems
Primary Growth Drivers
Technological advancements (+3.2% CAGR): Portable/tankless systems
Non-invasive treatments (+2.1% CAGR): Nasal cannula adoption
Respiratory disorder prevalence (+1.5% CAGR): PPHN, ARDS, COPD
Pulmonary care advances (+0.9% CAGR): 300ppm protocols

Key Market Trends & Highlights

The Inhaled Nitric Oxide No Delivery System Market is poised for growth driven by technological advancements and increasing demand for non-invasive treatments.

  • Technological advancements are enhancing the efficacy and safety of inhaled nitric oxide delivery systems.
  • North America remains the largest market, while Asia-Pacific is emerging as the fastest-growing region in this sector.
  • The 300 ppm segment dominates the market, whereas the 200 ppm segment is witnessing rapid growth due to its innovative applications.
  • Rising prevalence of respiratory disorders and growing awareness of non-invasive treatment options are key drivers propelling market expansion.

Market Size & Forecast

2024 Market Size 1.268 (USD Billion)
2035 Market Size 2.619 (USD Billion)
CAGR (2025 - 2035) 6.82%

Major Players

Mallinckrodt Pharmaceuticals (IE), Bellerophon Therapeutics (US), United Therapeutics Corporation (US), OxySure Therapeutics (US), AstraZeneca (GB), Pfizer Inc. (US), Novartis AG (CH), Eli Lilly and Company (US)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

Inhaled Nitric Oxide No Delivery System Market Trends

The Inhaled Nitric Oxide No Delivery System Market is currently experiencing a notable evolution, driven by advancements in medical technology and a growing understanding of nitric oxide's therapeutic potential. This market encompasses systems designed to deliver inhaled nitric oxide, a gas with vasodilatory properties, primarily used in treating respiratory conditions. The increasing prevalence of pulmonary hypertension and other related disorders has led to heightened demand for effective treatment options. Furthermore, the emphasis on non-invasive therapies is reshaping the landscape, as healthcare providers seek alternatives that minimize patient discomfort while maximizing therapeutic efficacy. In addition, regulatory bodies are progressively recognizing the benefits of inhaled nitric oxide, which may facilitate faster approvals for new delivery systems. The market appears to be influenced by ongoing research and development efforts aimed at enhancing the safety and effectiveness of these systems. As healthcare systems worldwide continue to prioritize patient-centered care, the Inhaled Nitric Oxide No Delivery System Market is likely to expand, reflecting a broader trend towards innovative solutions in respiratory therapy. This evolution suggests a promising future for both manufacturers and patients, as new technologies emerge to meet the growing needs of the healthcare sector.

Technological Advancements

Recent innovations in delivery mechanisms are enhancing the efficiency of inhaled nitric oxide systems. These advancements may lead to improved patient outcomes and greater acceptance among healthcare providers.

Regulatory Support

The evolving regulatory landscape appears to favor the introduction of new inhaled nitric oxide systems. This support could accelerate market growth and encourage further research into therapeutic applications.

Focus on Non-Invasive Treatments

There is a noticeable shift towards non-invasive treatment options in respiratory care. This trend suggests that inhaled nitric oxide systems may gain traction as preferred alternatives to traditional therapies.

Inhaled Nitric Oxide No Delivery System Market Drivers

Rising Prevalence of Respiratory Disorders

The increasing incidence of respiratory disorders, such as chronic obstructive pulmonary disease (COPD) and pulmonary hypertension, is a key driver for the Inhaled Nitric Oxide No Delivery System Market. According to recent estimates, millions of individuals are affected by these conditions, leading to a heightened demand for effective treatment options. Inhaled nitric oxide has emerged as a promising therapeutic agent, particularly for patients with severe pulmonary hypertension. The ability of inhaled nitric oxide to selectively dilate pulmonary vessels makes it a valuable tool in managing these disorders. As healthcare providers seek innovative solutions to improve patient outcomes, the Inhaled Nitric Oxide No Delivery System Market is likely to experience significant growth, driven by the need for targeted therapies that can enhance respiratory function.

Regulatory Support for Innovative Therapies

Regulatory bodies are increasingly supportive of innovative therapies, which is fostering growth in the Inhaled Nitric Oxide No Delivery System Market. Recent approvals and streamlined processes for novel inhaled nitric oxide formulations have encouraged manufacturers to invest in research and development. This regulatory environment not only facilitates the introduction of new products but also enhances the overall credibility of inhaled nitric oxide as a treatment option. As regulatory frameworks continue to evolve, they are likely to provide a conducive atmosphere for the expansion of the Inhaled Nitric Oxide No Delivery System Market, enabling companies to bring forth advanced therapies that meet the needs of patients and healthcare providers.

Technological Innovations in Delivery Systems

Technological advancements in the delivery systems for inhaled nitric oxide are propelling the Inhaled Nitric Oxide No Delivery System Market forward. Innovations such as portable delivery devices and improved nebulization techniques are enhancing the efficacy and convenience of treatment. These advancements allow for more precise dosing and better patient compliance, which are critical factors in managing respiratory conditions. The market is witnessing the introduction of novel devices that can deliver inhaled nitric oxide more effectively, thereby expanding its application in various clinical settings. As these technologies continue to evolve, they are expected to play a pivotal role in shaping the future of the Inhaled Nitric Oxide No Delivery System Market, potentially leading to increased adoption rates among healthcare providers.

Growing Awareness of Non-Invasive Treatment Options

There is a growing awareness among healthcare professionals and patients regarding the benefits of non-invasive treatment options, which is positively influencing the Inhaled Nitric Oxide No Delivery System Market. Non-invasive therapies are often preferred due to their reduced risk of complications and improved patient comfort. Inhaled nitric oxide, being a non-invasive treatment, aligns well with this trend, offering a safe alternative for managing conditions like pulmonary hypertension. As educational initiatives and clinical guidelines emphasize the importance of non-invasive approaches, the demand for inhaled nitric oxide is expected to rise. This shift in treatment paradigms is likely to contribute to the expansion of the Inhaled Nitric Oxide No Delivery System Market, as more healthcare providers adopt these innovative therapies.

Increasing Investment in Respiratory Health Research

The surge in investment directed towards respiratory health research is a significant driver for the Inhaled Nitric Oxide No Delivery System Market. Governments and private organizations are recognizing the urgent need to address respiratory diseases, leading to increased funding for research initiatives. This financial support is crucial for the development of new therapies and delivery systems for inhaled nitric oxide. As research progresses, it is anticipated that novel applications and formulations of inhaled nitric oxide will emerge, further enhancing its role in respiratory care. The influx of investment in this area is likely to stimulate innovation and growth within the Inhaled Nitric Oxide No Delivery System Market, ultimately benefiting patients with respiratory disorders.

Market Segment Insights

By Inhaled Nitric Oxide Concentration: 300 ppm (Largest) vs. 200 ppm (Fastest-Growing)

The inhaled nitric oxide concentration segment is characterized by varying levels that cater to different patient needs and conditions. Among these segments, the 300 ppm concentration holds the largest market share, reflecting its widespread acceptance and effectiveness in treating specific respiratory conditions. In comparison, the 200 ppm concentration is showing rapid growth, driven by increasing clinical preference and emerging studies highlighting its efficacy in various pediatric applications. As the market evolves, these concentrations are gaining recognition among healthcare providers, leading to changes in procurement practices and treatment protocols. Key growth trends in the inhaled nitric oxide concentration segment are largely attributed to advancements in technology and a deeper understanding of nitric oxide's therapeutic role in respiratory health. Additionally, the rising prevalence of conditions like pulmonary hypertension and the chronic obstructive pulmonary disease exacerbations are fostering demand for these concentrations. Regulatory approvals and ongoing clinical trials are also incentivizing healthcare providers to explore lower concentrations like 200 ppm, which may offer additional benefits, thereby impacting overall market dynamics positively.

200 ppm (Dominant) vs. 400 ppm (Emerging)

In the inhaled nitric oxide concentration segment, the 200 ppm level is emerging as a dominant choice among healthcare professionals, primarily due to its balance of efficacy and safety profiles. This concentration is increasingly preferred for treating neonates with hypoxic respiratory failure, making it a staple in neonatal intensive care units (NICUs). Its market position is bolstered by a growing body of clinical evidence supporting its use, leading to expanded adoption in various settings. On the other hand, the 400 ppm concentration is viewed as an emerging option that is still gaining traction. While it offers high potency and quick therapeutic effects, clinical caution regarding side effects has tempered its adoption. Continuous education and evidence generation around its safety and effectiveness are essential for 400 ppm to establish a stronger foothold in the competitive landscape.

By Delivery System: Nasal Cannula (Largest) vs. Ventilator (Fastest-Growing)

The Inhaled Nitric Oxide Delivery System Market is witnessing a diverse distribution among its segments, with Nasal Cannula leading the pack due to its simplicity and efficiency in delivering nitric oxide to patients. This method accounts for a significant share as it provides a non-invasive approach, enhancing patient comfort and compliance. Other methods like Tracheal Tube and Face Mask also hold notable shares, but Nasal Cannula's ease of use gives it the edge in prevalent healthcare settings. On the other hand, the Ventilator segment is recognized as the fastest-growing delivery system for inhaled nitric oxide. This rapid growth is driven by an increasing incidence of critically ill patients requiring advanced respiratory support, thus expanding the market's reach. Ventilators' ability to deliver precise doses of nitric oxide in controlled environments positions them as vital tools in managing severe respiratory conditions, indicating a shift in preference toward more technically advanced systems in the market.

Nasal Cannula (Dominant) vs. Tracheal Tube (Emerging)

Nasal Cannula remains the dominant delivery system in the Inhaled Nitric Oxide market due to its effective and user-friendly design, allowing for easy application in outpatient and home-care settings. It is well-regarded for optimizing patient comfort and promoting compliance among users. In contrast, the Tracheal Tube segment is seen as an emerging player that caters specifically to critical care environments. Although it is less frequently used than Nasal Cannula, it is essential in severe cases, offering a more direct route for gas delivery in intubated patients. As advancements in medical technology continue, the Tracheal Tube's role may expand, enhancing its market position alongside more traditional access methods.

By Patient Population: Newborns (Largest) vs. Older Adults (Fastest-Growing)

In the Inhaled Nitric Oxide No Delivery System Market, the patient population segment is primarily dominated by newborns due to the critical nature of respiratory conditions in neonatal care. This demographic holds the largest share, driven by the increasing incidence of persistent pulmonary hypertension of the newborn (PPHN) and other respiratory ailments. As healthcare systems enhance their capabilities to provide specialized care for newborns, this segment continues to expand and solidify its market leading position. On the other hand, older adults are the fastest-growing segment within this market. This growth is attributed to the rising prevalence of chronic respiratory diseases prevalent in the aging population, coupled with the increasing awareness and adoption of inhaled nitric oxide therapy to manage these conditions. Advances in clinical practices and a focus on improving patient outcomes drive the demand within this demographic, positioning it as a significant area for future growth in the market.

Newborns (Dominant) vs. Adults (Emerging)

Newborns represent the dominant segment in the Inhaled Nitric Oxide No Delivery System Market, characterized by the critical care requirements associated with respiratory challenges faced in early life. The emphasis on neonatal care and advancements in treatment protocols contribute to the steady demand for inhaled nitric oxide in this segment. Conversely, adults are emerging as a significant segment as respiratory disorders become more prevalent in this demographic, driven by lifestyle changes and environmental factors. The incorporation of inhaled nitric oxide therapy in adult treatment regimens is gaining traction, supported by increasing clinical studies showcasing its benefits. The adults segment reflects a shift towards addressing broader respiratory issues beyond neonatal care, heralding potential growth for inhaled nitric oxide applications.

By Indication: Pulmonary Hypertension (Largest) vs. Respiratory Distress Syndrome (Fastest-Growing)

The Inhaled Nitric Oxide No Delivery System Market showcases distinct segments with varying market shares. Among these, Pulmonary Hypertension stands out as the largest segment, characterized by heightened demand due to its critical role in management protocols. Following closely is the Respiratory Distress Syndrome segment, which, thanks to an increased incidence and proactive treatment strategies, is rapidly gaining traction in the market. Together, these segments are instrumental in shaping the overall demand for inhaled nitric oxide systems in therapeutic applications.

Pulmonary Hypertension (Dominant) vs. Respiratory Distress Syndrome (Emerging)

Pulmonary Hypertension remains the dominant indication in the Inhaled Nitric Oxide No Delivery System Market, supported by its established treatment protocols that emphasize nitric oxide's efficacy in vasodilation and improving oxygenation. Conversely, Respiratory Distress Syndrome is emerging as a significant player, particularly in pediatric care, where the demand for innovative treatment methods is growing. The rising awareness of the benefits of inhaled nitric oxide in managing acute respiratory failure underscores this shift. Both segments reflect a robust market dynamic, propelled by ongoing research and a growing clinical focus.

By End User: Hospitals (Largest) vs. Clinics (Fastest-Growing)

The Inhaled Nitric Oxide No Delivery System Market is primarily driven by hospitals, which command the largest market share due to their capacity to provide comprehensive care for patients with respiratory and cardiac conditions. Hospitals are equipped with advanced healthcare infrastructures and technologies, allowing the effective utilization of inhaled nitric oxide therapies. Clinics follow, experiencing notable demand but handling a smaller patient volume compared to hospitals, reflecting their secondary role in administering such treatments. Ambulatory Surgery Centers (ASCs) hold an even smaller share, primarily focusing on surgical procedures and often referring patients to larger hospital facilities for specialized respiratory care. Growth trends in this segment indicate a shift towards decentralized healthcare delivery models, favoring clinics and ASCs as emerging players in the market. As healthcare systems aim to reduce costs and improve patient access, clinics are gradually adopting inhaled nitric oxide therapies, contributing to their rapid growth. Regulatory support and technological innovations further encourage this trend, making it easier for these facilities to integrate advanced treatment options into their services, thus enhancing patient outcomes and expanding their market roles.

Hospitals (Dominant) vs. Clinics (Emerging)

Hospitals represent the dominant end user in the Inhaled Nitric Oxide No Delivery System Market, leveraging extensive medical resources and specialized staff to administer complex treatments. These institutions have well-established protocols for handling critical respiratory conditions, positioning them as leaders in nitric oxide therapy application. Clinics, identified as emerging players in this arena, have been increasingly integrating inhaled nitric oxide into their treatment regimens, focusing on outpatient care. With fewer administrative hurdles and the pursuit of cost-effective alternatives, clinics are evolving to provide similar offerings as hospitals, enhancing their competitiveness. This dynamic creates a more collaborative healthcare environment where hospitals and clinics share resources while improving access to life-saving therapies for patients.

Get more detailed insights about Inhaled Nitric Oxide No Delivery System Market
Request Free Sample

Regional Insights

North America : Market Leader in Innovation

North America is the largest market for inhaled nitric oxide no delivery systems, accounting for approximately 45% of the global market share. The region's growth is driven by increasing prevalence of respiratory diseases, advancements in medical technology, and supportive regulatory frameworks. The FDA's approval processes for innovative therapies further catalyze market expansion, fostering a conducive environment for research and development. The United States stands as the primary market, with significant contributions from Canada. Key players such as Mallinckrodt Pharmaceuticals and United Therapeutics Corporation are at the forefront, driving competition and innovation. The presence of established healthcare infrastructure and investment in R&D enhances the competitive landscape, ensuring a steady supply of advanced therapeutic options for patients.

Europe : Emerging Market with Potential

Europe is witnessing a growing demand for inhaled nitric oxide no delivery systems, holding approximately 30% of the global market share. The region's growth is propelled by increasing awareness of respiratory conditions and the rising adoption of advanced therapeutic solutions. Regulatory bodies like the European Medicines Agency (EMA) are actively promoting innovative treatments, which is expected to further enhance market dynamics in the coming years. Leading countries such as Germany, France, and the UK are driving this growth, supported by a robust healthcare system and significant investments in medical research. Key players like AstraZeneca and Novartis AG are expanding their portfolios to include inhaled therapies, intensifying competition. The collaborative efforts between public and private sectors are also fostering innovation, making Europe a promising market for inhaled nitric oxide therapies.

Asia-Pacific : Rapidly Growing Market

Asia-Pacific is emerging as a significant market for inhaled nitric oxide no delivery systems, accounting for approximately 20% of the global market share. The region's growth is driven by rising healthcare expenditures, increasing prevalence of respiratory diseases, and a growing awareness of advanced treatment options. Government initiatives aimed at improving healthcare infrastructure and access to innovative therapies are also contributing to market expansion. Countries like China, Japan, and India are leading the market, with substantial investments in healthcare and pharmaceutical sectors. The competitive landscape is characterized by the presence of both local and international players, including Bellerophon Therapeutics and OxySure Therapeutics. The increasing collaboration between healthcare providers and pharmaceutical companies is expected to enhance the availability of inhaled therapies in the region, further driving market growth.

Middle East and Africa : Untapped Market Potential

The Middle East and Africa region is gradually emerging in the inhaled nitric oxide no delivery systems market, holding about 5% of the global market share. The growth is primarily driven by increasing healthcare investments, rising awareness of respiratory diseases, and the need for advanced therapeutic solutions. Regulatory bodies are beginning to recognize the importance of innovative therapies, which is expected to catalyze market development in the coming years. Countries such as South Africa and the UAE are at the forefront of this growth, with increasing healthcare infrastructure and investment in medical technologies. The competitive landscape is still developing, with opportunities for both local and international players to establish a presence. As healthcare systems evolve, the demand for inhaled therapies is anticipated to rise, presenting significant opportunities for market entrants.

Inhaled Nitric Oxide No Delivery System Market Regional Image

Key Players and Competitive Insights

Major players in Inhaled Nitric Oxide No Delivery System Market industry are continuously looking for the development of new products. Leading Inhaled Nitric Oxide No Delivery System Market players are also adopting various marketing strategies like R&D, innovation and expansion of their production line to cater to the Inhaled Nitric Oxide No Delivery System Market development. The Inhaled Nitric Oxide No Delivery System Market Competitive Landscape reveals that the market is getting intense, with major players planning various strategies to gain a lion’s share of the market. ResMed is a leading company in the Inhaled Nitric Oxide No Delivery System Market. The company is headquartered in San Diego, California, and has operations in over 100 countries. ResMed develops, manufactures, and markets medical devices for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. The company's products include CPAP machines, oxygen concentrators, and ventilators. ResMed has a strong commitment to research and development, and its products are known for their high quality and innovation. Another major player in the Inhaled Nitric Oxide No Delivery System Market is GE Healthcare. The company is headquartered in Chicago, Illinois, and has operations in over 100 countries. GE Healthcare develops, manufactures, and markets a wide range of medical devices, including imaging systems, patient monitoring equipment, and anesthesia machines. The company's products are used in hospitals, clinics, and other healthcare settings around the world. GE Healthcare has a strong commitment to innovation, and its products are known for their advanced technology and reliability.

Key Companies in the Inhaled Nitric Oxide No Delivery System Market include

Industry Developments

The global inhaled nitric oxide (iNO) no-delivery system market is projected to reach USD 1.11 billion by 2023, exhibiting a CAGR of 6.8% from 2024 to 2032. The increasing prevalence of respiratory diseases, particularly among preterm infants, is driving market growth. Moreover, rising demand for non-invasive respiratory support and technological advancements in iNO delivery systems are contributing to market expansion. Recent developments include the launch of compact and portable iNO devices, making it easier to administer the therapy in various settings.

Additionally, research on the use of iNO in treating other respiratory conditions, such as acute respiratory distress syndrome (ARDS), is expected to create new market opportunities.

Future Outlook

Inhaled Nitric Oxide No Delivery System Market Future Outlook

The Inhaled Nitric Oxide No Delivery System Market is projected to grow at a 6.82% CAGR from 2025 to 2035, driven by increasing respiratory diseases and technological advancements.

New opportunities lie in:

  • Development of portable inhalation devices for home use Partnerships with hospitals for integrated care solutions Expansion into emerging markets with tailored product offerings

By 2035, the market is expected to achieve robust growth, positioning itself as a leader in respiratory therapies.

Market Segmentation

Inhaled Nitric Oxide No Delivery System Market End User Outlook

  • Hospitals
  • Clinics
  • Ambulatory Surgery Centers

Inhaled Nitric Oxide No Delivery System Market Indication Outlook

  • Pulmonary Hypertension
  • Respiratory Distress Syndrome
  • Asthma
  • Chronic Obstructive Pulmonary Disease

Inhaled Nitric Oxide No Delivery System Market Delivery System Outlook

  • Nasal Cannula
  • Tracheal Tube
  • Ventilator
  • Face Mask

Inhaled Nitric Oxide No Delivery System Market Patient Population Outlook

  • Newborns
  • Children
  • Adults
  • Older Adults

Inhaled Nitric Oxide No Delivery System Market Inhaled Nitric Oxide Concentration Outlook

  • 100 ppm
  • 200 ppm
  • 300 ppm
  • 400 ppm
  • 500 ppm

Report Scope

MARKET SIZE 2024 1.268(USD Billion)
MARKET SIZE 2025 1.354(USD Billion)
MARKET SIZE 2035 2.619(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 6.82% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled Mallinckrodt Pharmaceuticals (IE), Bellerophon Therapeutics (US), United Therapeutics Corporation (US), OxySure Therapeutics (US), AstraZeneca (GB), Pfizer Inc. (US), Novartis AG (CH), Eli Lilly and Company (US)
Segments Covered Inhaled Nitric Oxide Concentration, Delivery System, Patient Population, Indication, End User, Regional
Key Market Opportunities Advancements in inhalation technology enhance therapeutic applications in the Inhaled Nitric Oxide No Delivery System Market.
Key Market Dynamics Rising demand for inhaled nitric oxide therapies drives innovation and competition among delivery system manufacturers.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the projected market valuation for the Inhaled Nitric Oxide No Delivery System Market in 2035?

The projected market valuation for the Inhaled Nitric Oxide No Delivery System Market in 2035 is 2.619 USD Billion.

What was the market valuation for the Inhaled Nitric Oxide No Delivery System Market in 2024?

The market valuation for the Inhaled Nitric Oxide No Delivery System Market in 2024 was 1.268 USD Billion.

What is the expected CAGR for the Inhaled Nitric Oxide No Delivery System Market from 2025 to 2035?

The expected CAGR for the Inhaled Nitric Oxide No Delivery System Market during the forecast period 2025 - 2035 is 6.82%.

Which companies are considered key players in the Inhaled Nitric Oxide No Delivery System Market?

Key players in the market include Mallinckrodt Pharmaceuticals, Bellerophon Therapeutics, United Therapeutics Corporation, and others.

What are the projected revenues for the 100 ppm concentration segment in 2025?

The projected revenues for the 100 ppm concentration segment in 2025 are expected to range from 0.254 to 0.516 USD Billion.

How does the revenue for the Nasal Cannula delivery system compare to other delivery systems?

The revenue for the Nasal Cannula delivery system is projected to be between 0.38 and 0.78 USD Billion, making it one of the leading delivery systems.

What is the anticipated revenue for the Pulmonary Hypertension indication segment in 2025?

The anticipated revenue for the Pulmonary Hypertension indication segment in 2025 is expected to range from 0.5 to 0.9 USD Billion.

Which patient population segment is projected to generate the highest revenue in 2025?

The Newborns patient population segment is projected to generate the highest revenue, estimated between 0.4 and 0.8 USD Billion.

What is the expected revenue range for hospitals as end users of the Inhaled Nitric Oxide No Delivery System?

The expected revenue range for hospitals as end users is projected to be between 0.76 and 1.55 USD Billion.

How does the revenue for the Chronic Obstructive Pulmonary Disease indication segment compare to Asthma?

The revenue for the Chronic Obstructive Pulmonary Disease indication segment is projected to be between 0.268 and 0.719 USD Billion, which is higher than the Asthma segment, estimated at 0.2 to 0.4 USD Billion.

Author
Author
Author Profile
Chitranshi Jaiswal LinkedIn
Team Lead - Research
Chitranshi is a Team Leader in the Chemicals & Materials (CnM) and Energy & Power (EnP) domains, with 6+ years of experience in market research. She leads and mentors teams to deliver cross-domain projects that equip clients with actionable insights and growth strategies. She is skilled in market estimation, forecasting, competitive benchmarking, and both primary & secondary research, enabling her to turn complex data into decision-ready insights. An engineer and MBA professional, she combines technical expertise with strategic acumen to solve dynamic market challenges. Chitranshi has successfully managed projects that support market entry, investment planning, and competitive positioning, while building strong client relationships. Certified in Advanced Excel & Power BI she leverages data-driven approaches to ensure accuracy, clarity, and impactful outcomes.
Get In Touch
Leave a Comment
Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓